RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets plasma-based biologics designed to treat Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, today announced the closing of an underwritten public offering of approximately 19.5 million shares of its common stock at a public offering price of $2.15 per share. The offering includes the full exercise of the overallotment of approximately 2.5 million shares of common stock of the Company, which were offered and sold in connection with the 30-day option granted by the Company to the underwriters to purchase additional shares of common stock of the Company. The net proceeds to the Company from this offering were approximately $39.1 million, after deducting underwriters’ discounts and commissions and other offering expenses payable by the Company.
Raymond James & Associates, Inc. acted as the sole book-running manager and representative of the underwriters for the offering. Ladenburg Thalmann & Co. Inc. acted as lead manager for the offering.
About ADMA Biologics, Inc. (ADMA)
ADMA is a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets plasma-based biologics designed to treat PIDD and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA has received U.S. Patents 9,107,906 and 9,714,283 related to certain aspects of its product candidate, RI-002. For more information, please visit www.admabiologics.com.
